***In silico* modeling and simulation of neuroendocrine-immune modulation through adrenergic and 17 β -estradiol receptors in lymphocytes show differential activation of cyclic adenosine monophosphate (cAMP)**

Priyanka, H. P^{1,2}, Thiagaraj, A.³, Nair, R.S.², Krithika, G.⁴, Hima, L.¹, Hopper, W. ³,

ThyagaRajan, S. ¹

¹Integrative Medicine Laboratory, Department of Biotechnology, School of Bioengineering, SRM University, Kattankulathur 603203, India; ² Inspire Lab, Institute of Advanced Research in Health Sciences, Tamil Nadu Government Multi Super Speciality Hospital, Chennai 600002, India; ³Department of Bioinformatics, School of Bioengineering, SRM University, Kattankulathur 603203, India; ⁴Centre of Advanced Study in Crystallography and Biophysics, University of Madras Guindy Campus, Chennai 600025, India

¹Corresponding author:

Hannah P. Priyanka,
Institute of Advanced Research in Health Sciences
Tamil Nadu Government Multi Super Speciality Hospital
Omandurar Government Estate
Chennai 600002
Tamil Nadu, INDIA
Email: hannahpriyanka@gmail.com
Phone: 91-9841883355

Keywords:

Immunomodulation, T-cell, norepinephrine, 17 β -estradiol, p-ERK, IFN- γ

Word Count: 5039 Words

Running Head:

Estrogen and adrenergic signaling in silico

Abstract

Sympathetic innervation of lymphoid organs and presence of 17β -estradiol (estrogen or E₂) and adrenergic receptors (ARs) on lymphocytes suggests that sympathetic stimulation and hormonal activation may influence immune functions. Simulation of these pathways may help to understand the dynamics of neuroendocrine-immune modulation at the cellular and molecular level.

Dose- and receptor-dependent effects of 17β -estradiol and AR sub-type-specific agonists were established in vitro on lymphocytes from young male Sprague-Dawley rats and modeled in silico using MATLAB Simbiology toolbox. Kinetic principles were assigned to define receptor-ligand dynamics and concentration/time plots were obtained using Ode15s solvers at different time intervals for key regulatory molecules. Comparisons were drawn between in silico and *in vitro* data for validating the constructed model with sensitivity analysis of key regulatory molecules to assess their individual impacts on the dynamics of the system.

Adrenergic activation triggered pro-apoptotic signals while 17β -estradiol enhanced survival signals showing contradictory effects as observed in vitro. Treatment of lymphocytes with 17β -estradiol shows ten-fold increase in survival signals in a dose-dependent manner. cAMP (cyclic adenosine monophosphate) activation is crucial for the activation of survival signals through p-ERK (Extracellular Signal-Regulated Kinase) and p-CREB (cAMP Responsive Element Binding) protein.

Thus, the cross-talk between 17β -estradiol and adrenergic signaling pathways determines lymphocyte functions in a receptor subtype- and co-activation-dependent manner in health and disease.

1.0 Introduction

The neuroendocrine-immune network is a complex inter-regulatory system with wide plasticity in order to maintain systemic homeostasis [1-3]. In females, the cyclic fluctuations in the levels of gonadal hormones especially, 17β -estradiol affect the functioning of immune effector cells by binding to specific estrogen receptors [ER; 4-7].

In the periphery, *in vitro* and *in vivo* 17β -estradiol-stimulation has been shown to enhance splenocyte proliferation and cytokine production through the alteration of specific signaling molecules [2, 4, 8]. Estrogen enhances splenocyte proliferation, Interferon- γ (IFN- γ) expression, through p-ERK and p-CREB signals, enhances activity of antioxidant enzymes (AOE) including superoxide dismutase (SOD) and catalase (CAT) and increases splenocyte nitric oxide (NO) expression dose dependently [4]. In the resting state, the close apposition of T-lymphocytes in direct synaptic association with sympathetic noradrenergic (NA) nerve fibers that innervate the lymphoid organs renders them highly responsive to norepinephrine [NE; 7, 9-13]. Since both 17β -estradiol and NE mediate their effects on lymphocytes through their specific receptors, their downstream effects are dependent upon the kinetic parameters that govern receptor-ligand interactions [10, 14-16]. Previous studies from our laboratory and others have shown that both 17β -estradiol and norepinephrine signaling cascades involve similar molecules (p-ERK, p-CREB, cAMP and p-Akt) in modulating the expression of similar cytokines (IFN- γ and interleukin-2 (IL-2)) thereby, altering cell-mediated immune functions [2, 4, 17-18]. Thus, the scope of cross-talk between the two pathways during multiple ligand-receptor interactions is complex. Considering that NE can

bind to $\alpha 1$ -/ $\alpha 2$ - or $\beta 1$ -/ $\beta 2$ -/ $\beta 3$ - adrenoceptors (AR) on lymphocytes and 17β -estradiol can bind to cytosolic or nuclear 17β -estradiol receptors (cER and nER) and initiate signals that target similar down-stream signaling molecules, the underlying kinetic parameters can influence the outcome of the cross-talk through synergistic, additive or diminutive effects.

Our lab has delineated these effects in splenocytes using adrenergic receptor-specific agonists and antagonists in the presence and absence of estrogen [17, 18]. $\alpha 1$ -AR agonist Phenylephrine enhances p-ERK and p-CREB expression, while $\alpha 2$ -AR agonist clonidine enhances p-Akt expression and may play a crucial role in the sustenance of naïve cells in the secondary lymphoid organs [17]. $\beta 2$ -AR agonist terbutaline enhances the expression of p-ERK, p-CREB and p-Akt signals, antioxidant enzyme activities including CAT and SOD and the production of NO in splenocytes [18]. In this study, we have superimposed the four signaling cascades (Estrogen signaling, $\alpha 1$ -AR signaling, $\alpha 2$ -AR signaling and $\beta 2$ -AR signaling) from our *in vitro* studies, and created a dynamic model of resting lymphocyte functions. In order to simulate real time events we have used kinetic principles that govern receptor-ligand activation based on secondary data from available literature along with concentration data from *in vitro* studies published from our laboratory [4,17,18]. The present study aims to create a computational model of the pathways studied *in vitro* so that the scope of the intercommunication between these pathways can be better understood in health and disease.

2.0 Methods

2.1 Model building

The model was built using both primary and secondary data sources. The dose- and receptor-dependent effects of 17β -estradiol and AR sub-type-specific agonists were established *in vitro* on lymphocytes from young male Sprague-Dawley rats in previous studies published by our

laboratory [17,18]. Briefly, splenic lymphocytes were isolated from young male Sprague-Dawley rats and treated with different doses of Estrogen [4], AR- α agonists phenylephrine and clonidine [17] and AR- β agonist terbutaline [18] for a period of 24-72 hours. In these studies, the concentration of the signaling molecules, cytokines, and other secondary molecules was determined using ELISA and these data were used to construct the model (Tables 1, 2). The possible cross-talk pathway was mapped using receptor-specific inhibitors and inhibitors of signal transduction molecules and was modeled *in silico* using the MATLAB Simbiology toolbox [MATLAB and SimBiology toolbox Release 2019a, The Mathworks, inc., Natick, Massachusetts, United States]. Receptor-ligand dynamics were defined based on kinetic principles from available literature and previous studies from our laboratory [4, 17,18]. State versus time plots were obtained using Ode15s solvers at 24 hours or 72 hrs for long-term effects on lymphocyte functions. Comparisons were drawn between *in silico* and *in vitro* data for validating the constructed model. Sensitivity analysis was performed on key regulatory molecules to assess their individual impacts on the dynamics of the system. The model was uploaded in Github database.

(<https://github.com/Anandt1082/Neuroimmunomodulation-by-estrogen-and-adrenergic-agonists.git>).

2.1.1 Model

The model was built to show an interconnected network of four signaling pathways on the basis of *in vitro* studies conducted in our laboratory including:

1. α 1-adrenoceptor signaling [17]; (Table 1A, Figure 1A)

Construction of the α 1-adrenoceptor signaling pathway was based on the data from our lab and others that showed that stimulating the α 1-AR in splenocytes with 10^{-6} M and 10^{-9} M specific agonist phenylephrine did not alter splenocyte proliferation but enhanced survival

signaling molecules including p-ERK and p-CREB [17]. In order to simulate the receptor-ligand reactions in real time, the receptor ligand interactions were defined for $\alpha 1$ -AR as shown in table 2A [19]. The concentrations of ERK and CREB used in the model were based on the data from the published in vitro study determined using ELISA [17]. Downstream signaling cascades were assumed to follow the law of mass action. Molecules for which concentrations were not known such as PKA and CBP were assigned arbitrary values (257 nM) that did not impose a constraint on the system.

2. $\alpha 2$ -adrenoceptor signaling [17]; (Table 1B, Figure 1A):

$\alpha 2$ -AR signaling was constructed based on the data obtained from our study showing that incubation of $\alpha 2$ -AR specific agonist Clonidine (10^{-9} M- 10^{-6} M) enhanced Akt signaling cascade [17]. Although our study showed a decrease in cellular proliferation in response to clonidine, there was no reversal upon co-treatment with specific antagonist idazoxan. It is possible that $\alpha 2$ -AR stimulation is necessary for the sustenance of nerve fibres through activation of Bcl-2 downstream to Akt signaling [20]. The receptor ligand interactions for $\alpha 2$ -AR are defined in table 2A [21]. The concentration for Akt was obtained from the in vitro study using ELISA [17]. Downstream signaling cascades were assumed to follow the law of mass action. Molecules for which concentrations were not known such as BCL-2 were assigned arbitrary values (300 nM) that did not impose a constraint on the system.

3. $\beta 2$ -adrenoceptor signaling [18]; (Table 1C, Figure 1A):

Construction of the $\beta 2$ -adrenoceptor signaling was based on the data obtained from the published in vitro study [18]. Stimulation of splenocytes using the $\beta 2$ -adrenoceptor agonist terbutaline significantly enhanced p-ERK and p-CREB expression, activity of SOD and CAT through PKA. Terbutaline treatment also enhanced IL-2 expression through p-Akt.

p-Akt expression also enhances the activity of iNOS leading to an increase in NO expression. NO can react with superoxides and form peroxynitrites that may accumulate and lead to apoptosis, or trigger CAAT, CEBP, CHOP, BCL-2, leading to dimerization of BCL-2-Bax complex leading to apoptosis [22]. The receptor ligand interactions for β 2-AR and IFN- γ are defined in table 2A [23,24]. The concentration for ERK, CREB, Akt, NO, IFN- γ , IL-2 were obtained from the in vitro study using ELISA [17]. Downstream signaling cascades were assumed to follow the law of mass action. Molecules for which concentrations were not known such as PI3K, PKA, CBP (257 nM), SOD, CAT, iNOS (0 units), CAAT, CEBP, CHOP, BAX, BCL-2, O₂- (0 units) were assigned arbitrary initial values that did not impose a constraint on the system.

4. 17 β -estradiol signaling through ERs and GPCRs [4]; (Table 1D, Figure 1B) and their respective kinetic parameters outlined in Table 2. Estrogen signaling was constructed based on the data from the in vitro study published from our lab [4]. Splenocytes stimulated with estrogen showed enhanced expression of ERK and CREB signals through PKA and cAMP by estrogen binding to GPCRs, leading to the expression of IFN- γ . IFN- γ can bind to IFN- γ receptor, activate PI3K, Ras, Raf, MEK, ERK and CREB cascades leading to survival signals. Estrogen can bind to estrogen receptors, stimulate Shc, Grb-2, Sos, activate PI3K, Akt, iNOS leading to NO expression, activation of CAAT, CEBP, CHOP and induce pro-apoptotic signals through Bcl-2/Bax cascades. NO can also bind with superoxides leading to the production of peroxynitrites that serve as an apoptotic signal. On the other hand, Estrogen also promotes the expression of SOD and CAT through p-ERK leading to scavenging of the excess superoxides leading to survival signals [4]. Estrogen can also bind

to nuclear receptors and lead to the production of IFN- γ . The receptor ligand interactions for estrogen receptors, IFN- γ receptors are defined in table 2A [24,25]. The concentration for ERK, CREB, Akt, NO, IFN- γ were obtained from the in vitro study using ELISA [17]. Downstream signaling cascades were assumed to follow the law of mass action. Molecules for which concentrations were not known such as PI3K, PKA, CBP (257 nM), SOD, CAT, iNOS (0 units), CAAT, CEBP, CHOP, BAX, BCL-2, O2- (0 units) were assigned arbitrary initial values that did not impose a constraint on the system. Enzyme kinetics for CAT, SOD and iNOS were defined using the Henri-Michaelis-Menten equation.

Table 1: Reaction table and kinetics for α 1-adrenoceptor signaling (1A), α 2-adrenoceptor signaling (1B), β 2-adrenoceptor signaling (1C) and 17 β -estradiol signaling through ERs and GPCRs (1D).

1A	Reaction	Kinetics	References
1	$[AR - \alpha 1] + [Phenylephrine] \rightarrow [RL1]$	$vm * [Phenylephrine] / (km + [Phenylephrine])$	[26-29]
2	$[CREB] + [RL1] \rightarrow [p - CREB]$	$kn.[CREB].[RL1]$	
3	$[p - CREB] + [CBP] \rightarrow [CBP - CREB]$	$ct.[p - CREB].[CBP]$	
4	$[CBP] - [p - CREB] + [DNA] \rightarrow [mRNA1] + [mRNA2]$	$tr.[CBP - p - CREB].[DNA]$	
5	$[mRNA1] \rightarrow [SurvivalSignal]$	$as.[mRNA1]$	

1B	Reaction	Kinetics	References
1	$[AR - \alpha 2] + [Clonidine] \rightarrow [RL2]$	$va * [Clonidine] / (kn + [Clonidine])$	[30-33]
2	$[PI3K^*] + [Akt] + [RL2] \rightarrow [p - Akt]$	$at.[PI3K^*].[Akt].[RL2]$	
3	$[RL2] + [PKA^*] \rightarrow [PKA]$	$ml.[RL2].[PKA^*]$	
4	$[p - Akt] + [BCL2] \rightarrow [BCL2^*]$	$bc.[p - Akt].[BCL2]$	
5	$[BCL2^*] \rightarrow [SurvivalSignal]$	$aps.[BCL2^*]$	

1C	Reaction	Kinetics	References

1	$[\beta 2 - AR] + [Terbutaline] \rightarrow [RL3]$	$bt.[Terbutaline]/(kbt + [Terbutaline])$	[34-43]
2	$[RL3] + [PKA] \rightarrow [PKA^*]$	$gh.[RL3].[PKA]$	
3	$[RL3] + [PI3K] \rightarrow [PI3K^*]$	$jk.[RL3].[PI3K]$	
4	$[PKA^*] + [ERK] \rightarrow [p - ERK]$	$fd.[PKA^*].[ERK]$	
5	$[p - ERK] + [CREB] \rightarrow [p - CREB] + [ERK]$	$pe.[p - ERK].[CREB]$	
6	$[p - CREB] + [CBP] \rightarrow [CBP - CREB]$	$ct.[p - CREB].[CBP]$	
7	$[CBP] - [p - CREB] + DNA \rightarrow [mRNA1] + [mRNA2]$	$tr.[CBP - p - CREB].[DNA]$	
8	$[p - Akt] + [DNA] \rightarrow [mRNA2 - 1 - 1]$	$kj.[p - Akt].[DNA]$	
9	$[mRNA2 - 1 - 1] \rightarrow [iNOS]$	$hg.[mRNA2 - 1 - 1]$	
10	$L - Arg + iNOS \rightarrow NO$	$hg.L - Arg/(fd + [L - Arg])$	
11	$[NO] + [CAAT] \rightarrow [C / EBP]$	$vm.[NO].[CAAT]$	
12	$[C / EBP] \rightarrow [CHOP]$	$cvc.[CAAT]/(kc + [CAAT])$	
13	$[DNA] + [CHOP] \rightarrow [mRNA2 - 1]$	$vch.[CHOP]/(kch + [CHOP])$	
14	$[mRNA2 - 1] \rightarrow [BAX]$	$fbax.[mRNA2 - 1]$	
15	$[BAX] + [BCL2] \rightarrow [BCL2 - BAX]2'$	$vbax.[BAX]/(kbax + [BAX])$	
16	$[BCL2 - BAX]2 \rightarrow [ApoptoticSignal]$	$vx.[BCL2 - BAX]2$	
17	$[DNA] + [p - Akt] \rightarrow [mRNA3]$	$kj.[DNA].[p - AKt]$	
18	$[mRNA3] \rightarrow [IL - 2]$	$kl.[mRNA3]$	
19	$[IL - 2] \rightarrow [SurvivalSignal]$	$kj.[IL - 2]$	
20	$[p - ERK] + DNA \rightarrow [mRNA6]$	$f1.[p - ERK].[DNA]$	[18]
21	$[Superoxides] + [CAT] \rightarrow [SurvivalSignal]$	$v1.[Superoxides]/(k1 + [Superoxides])$	
22	$[p - ERK] + DNA \rightarrow [mRNA7]$	$jh.[p - ERK].[DNA]$	
23	$[Superoxides] + [SOD] \rightarrow [SurvivalSignal]$	$v2.[Superoxides]/(k2 + [Superoxides])$	
24	$[Superoxides] + [NO] \rightarrow [Peroxynitrite]$	$gf.[Superoxides].[NO]$	
25	$[mRNA6] \rightarrow [CAT]$	$kj.[mRNA6]$	
26	$[mRNA7] \rightarrow [SOD]$	$kj.[mRNA7]$	

1D	Reaction	Kinetics	References
1	$[17\beta - Estradiol] + [GPCR] \rightarrow [cAMP]$	$Vm2.[\beta - Estradiol]/(kml + [17\beta - Estradiol])$	
2	$[cAMP] + [PKA] \rightarrow [PKA^*]$	$pk.[cAMP].[PKA]$	
3	$[ER] + [17\beta - Estradiol] \rightarrow [E - ER]$	$erb.[ER1].[17\beta - Estradiol]$	

4	$[E - ER] + [shc - grb2sos] \rightarrow [E - ER - shc - grb2sos]$	$eg.[E - ER].[shc - grb2sos]$	[44-50]
5	$[E - ER - shc - grb2sos] + [PI3K] \rightarrow [PI3K^*]$	$ep.[E - ER - shc - grb2sos].[PI3K]$	
6	$[E - ER] + [shc - grb2sos] + [RAS] \rightarrow [RAS^*]$	$era.[E - ER].[shc - grb2sos].[RAS]$	
7	$[RAF] + [RAS^*] \rightarrow [RAF^*]$	$kc.RAF^*.RAS^*$	
8	$[MEK] + [RAF^*] \rightarrow [MEK - RAF^*]$	$mek.[MEK].[RAF^*]$	
9	$[MEK - RAF^*] \rightarrow [MEK - p] + [RAF]$	$mekp.[MEK - RAF^*]$	
10	$[MEK - p] + [RAF^*] \rightarrow [MEK - p - RAF^*]_2$	$rm.[MEK - p].[RAF^*]$	
11	$[MEK - p - RAF^*]_2 \rightarrow [MEK - pp] + [RAF]$	$mpp.[MEK - p - RAF^*]_2$	
12	$[ERK] + [MEK - pp] \rightarrow [p - ERK]$	$ka2.[ERK].[MEK - pp]$	
13	$[p - ERK] + [p - CREB] \rightarrow [p - CREB] + [ERK]$	$pe.[p - ERK].[CREB]$	
14	$[p - CREB] + [CBP] \rightarrow [CBP - CREB]$	$ct.[p - CREB].[CBP]$	
15	$[CBP] - [p - CREB] + [DNA] \rightarrow [mRNA1] + [mRNA2]$	$tr.[CBP - p - CREB].[DNA]$	
16	$[mRNA2] \rightarrow [IFN - \gamma]$	$ifp.[mRNA2]$	
17	$[mRNA2] \rightarrow [SurvivalSignal]$	$bnb.[mRNA2]$	
18	$[PI3K^*] + [Akt] \rightarrow [p - Akt]$	$at.[PI3K^*].[Akt]$	
19	$[p - Akt] + [DNA] \rightarrow [mRNA2 - 1 - 1]$	$kj.[p - Akt].[DNA]$	
20	$[mRNA2 - 1 - 1] \rightarrow [iNOS]$	$hg.[mRNA2 - 1 - 1]$	
21	$L - Arg + iNOS \rightarrow NO$	$hg.L - Arg / (fd + [L - Arg])$	
22	$[NO] + [CAAT] \rightarrow [C / EBP]$	$vm.[NO].[CAAT]$	
23	$[C / EBP] \rightarrow [CHOP]$	$cvc.[CAAT] / (kc + [CAAT])$	
24	$[DNA] + [CHOP] \rightarrow [mRNA2 - 1]$	$vch.[CHOP] / (kch + [CHOP])$	
25	$[mRNA2 - 1] \rightarrow [BAX]$	$fbax.[mRNA2 - 1]$	
26	$[BAX] + [BCL2] \rightarrow [BCL2 - BAX]_2'$	$vbax.[BAX] / (kbax + [BAX])$	
27	$[BCL2 - BAX]_2 \rightarrow [ApoptoticSignal]$	$vx.[BCL2 - BAX]_2$	
28	$[17\beta - Estradiol] + [cER] \rightarrow [E - cER]$	$ecr.[17\beta - Estradiol].[cER]$	
29	$E - cER \rightarrow [E - cER]_2$	$ed.[E - cER]$	
30	$[E - cER]_2 + [DNA] \rightarrow [mRNA2]$	$nt.[E - cER]_2.[DNA]$	
31	$[mRNA2] \rightarrow [IFN - \gamma]$	$ifn.[mRNA2]$	
32	$[IFNGR] + [IFN - \gamma] \rightarrow [IFN\gamma - IFNGR]$	$vm.[CREB] / (kd + [CREB])$	

33	$[IFN\gamma - IFNGR] \rightarrow [IFN\gamma - IFNGR]_2$	$rd.[IFN\gamma - IFNGR]$	[4,17,18]
34	$[IFN\gamma - IFNGR]_2 \rightarrow [IFN\gamma - IFNGR^*]_2$	$rc.[IFN\gamma - IFNGR]_2$	
35	$[IFN\gamma - IFNGR^*]_2 + [RAS] + [shc - grb2sos] \rightarrow [RAS^*]$	$kx.[IFN\gamma - IFNGR^*]_2.[RAS^*].[shc - grb2sos]$	
36	$[p - ERK] + DNA \rightarrow [mRNA6]$	$f1.[p - ERK].[DNA]$	
37	$[Superoxides] + [CAT] \rightarrow [SurvivalSignal]$	$v1.[Superoxides]/[k1 + Superoxides]$	
38	$[p - ERK] + DNA \rightarrow [mRNA7]$	$jh.[p - ERK].[DNA]$	
39	$[Superoxides] + [SOD] \rightarrow [SurvivalSignal]$	$v2.[Superoxides]/[k2 + Superoxides]$	
40	$[Superoxides] + [NO] \rightarrow [Peroxynitrite]$	$gf.[Superoxides].[NO]$	
41	$[mRNA6] \rightarrow [CAT]$	$kj.[mRNA6]$	
42	$[mRNA7] \rightarrow [SOD]$	$kj.[mRNA7]$	

Table 2: Receptor Binding maxima and Kd values (A), Signaling Molecule concentrations (B) and Ligand concentrations (C) as incorporated in the model.

2A	Receptor	Bmax	Kd (nM)	Reference
1.	$\alpha 1$ -AR	175.3 (fM/10 ⁶ cells)	0.65	[19]
2.	$\alpha 2$ -AR	19.9 (fM/10 ⁶ cells)	3.7	[21]
3.	$\beta 2$ -AR	1222 sites/cell	19.9	[23,24]
4.	IFN-gR	708±14 receptors/cell	0.9±0.2	[24]
5.	cER	0.6204 (fM/mg protein)	5.5	[25]
6.	nER	(0.136 fm/mcg dna)	-	[25]

2B	Signaling Molecules	Concentration (nM)	Reference
1.	ERK	251	[17]
2.	CREB	245.6	

3.	Akt	219	
4.	IFN-g	560	

2C	Signaling Moelcules	Concentration	Reference
1.	Phenylephrine	10^{-6} M	[17, 18]
2.	Clonidine	10^{-6} M	
3.	Terbutaline	10^{-6} M	
4.	Estrogen	10^{-8} M	

2.2 Simulations

Simulations were performed using Ode15s solvers for 24 hours and 72 hours depending upon the signals studied. The Mcode is included in the supplementary evidence. The model was tested for various combinations as follows and the figures are shown in supplementary evidence:

A. Estrogen Signaling: (Supplementary Figures 1-4)

a. Simulation Conditions:

- i. Terbutaline=0 M;
- ii. Phenylephrine=0 M;
- iii. Clonidine=0 M;
- iv. E₂= 10^{-3} M, 10^{-6} M, 10^{-9} M
- v. Time : 24 hours, 72 hours

B. Adrenergic Signaling:

a. Simulation Condition-1: Terbutaline Signaling (Supplementary Figures 5-8)

- i. Terbutaline= 10^{-3} M, 10^{-6} M, 10^{-9} M;
- ii. Phenylephrine= 10^{-6} M;
- iii. Clonidine= 10^{-6} M;
- iv. E₂= 0 M
- v. Time : 24 hours, 72 hours

b. Simulation Condition-2: Phenylephrine Signaling (Supplementary Figures 9-12)

- i. Terbutaline= 10^{-6} M;
- ii. Phenylephrine= 10^{-3} M, 10^{-6} M, 10^{-9} M;
- iii. Clonidine= 10^{-6} M;

- iv. $E_2 = 0 \text{ M}$
    - v. Time : 24 hours, 72 hours
  - c. Simulation Condition-3: Clonidine Signaling (Supplementary Figures 13-16)
    - i. Terbutaline= 10^{-6} M ;
    - ii. Phenylephrine= 10^{-6} M ;
    - iii. Clonidine= 10^{-3} M , 10^{-6} M , 10^{-9} M ;
    - iv. $E_2 = 0 \text{ M}$
    - v. Time : 24 hours, 72 hours
- C. Adrenergic+Estrogen Signaling
- a. Simulation Condition-1: Terbutaline+Estrogen Signaling (Supplementary Figures 17-20)
    - i. Terbutaline= 10^{-3} M , 10^{-6} M , 10^{-9} M ;
    - ii. Phenylephrine= 10^{-6} M ;
    - iii. Clonidine= 10^{-6} M ;
    - iv. $E_2 = 10^{-8} \text{ M}$
    - v. Time : 24 hours, 72 hours
  - b. Simulation Condition-2: Phenylephrine+Estrogen Signaling (Supplementary Figures 21-24)
    - i. Terbutaline= 10^{-6} M ;
    - ii. Phenylephrine= 10^{-3} M , 10^{-6} M , 10^{-9} M ;
    - iii. Clonidine= 10^{-6} M ;
    - iv. $E_2 = 10^{-8} \text{ M}$
    - v. Time : 24 hours, 72 hours
  - c. Simulation Condition-3: Clonidine+Estrogen Signaling (Supplementary Figures 24-28)
    - i. Terbutaline= 10^{-6} M ;
    - ii. Phenylephrine= 10^{-6} M ;
    - iii. Clonidine= 10^{-3} M , 10^{-6} M , 10^{-9} M ;
    - iv. $E_2 = 10^{-8} \text{ M}$
    - v. Time : 24 hours, 72 hours

For signaling molecules including p-ERK, p-Akt, p-CREB, and cAMP, cytokines including IL-2 and IFN- γ , antioxidant enzymes (SOD and CAT) and superoxides/peroxynitrites, the simulations were performed up to 24 hours similar to the in vitro study. Finally, for survival vs. apoptotic signals, the simulations were carried out for 72 hours. Since all the adrenergic receptors are activated by the same ligand norepinephrine, physiologically, the simulations were run for different doses of one receptor subtype (e.g., terbutaline 10^{-3} M , 10^{-6} M , 10^{-9} M) while allowing

for a mid-range activity in the other two (clonidine 10^{-6} M, phenylephrine 10^{-6} M) in the presence (10^{-8} M) and absence (0 M) of estrogen. Key regulatory molecules were scanned, and their sensitivities were analyzed at 24 hours for each of the ligands used (Supplementary Figures 1D-28D; M Code attached as Supplementary Index-2). Parameter sensitivity analysis was run for the initial concentrations of all the parameters included in the study (Table 3).

Table 3: Parameter sensitivity scan in fM for 24 hours for Estrogen (E2 10^{-9} M), and adrenergic agonists, Terbutaline (Ter 10^{-9} M), Phenylephrine (Phe 10^{-9} M), Clonidine (Clo 10^{-9} M), alone and in combination with estrogen.

Parameter Sensitivity							
Parameters	E2 10^{-9} M	Ter 10^{-9} M	E2+Ter 10^{-9} M	Phe 10^{-9} M	E2+Phe 10^{-9} M	Clo 10^{-9} M	E2+Clo 10^{-9} M
Ras	0	0	0	0	0	0	0
Raf	0	0	0	0	0	0	0
Mek	0	0	0	0	0	0	0
CAAT	0	0	0	0	0	0	0
BCL2	0	0	0	0	0	0	0
CHOP	0	0	0	0	0	0	0
CREB	0	8×10^{-4}	0	8×10^{-4}	0	8×10^{-4}	0
ERK	0	0	0	0	0	0	0
NO	0	0	0	0	0	0	0
PKA	0	8×10^{-4}	0	8×10^{-4}	0	8×10^{-4}	0
SOD	0	0	0	0	0	0	0
IFN-g	0	4×10^{-4}	0	4×10^{-4}	0	4×10^{-4}	0
IL2	0	0	0	0	0	0	0
L-arg	0	0	0	0	0	0	0
CAMP	7.8×10^{-4}	0	7.8×10^{-4}	0	7.8×10^{-4}	0	7.8×10^{-4}
cbp	0	8×10^{-4}	0	8×10^{-4}	0	8×10^{-4}	0
iNOS	0	0	0	0	0	0	0
pi3K	0	0	0	0	0	0	0
Superoxides	0	0	0	0	0	0	0
Survival signal	0	12×10^{-4}	0	12×10^{-4}	0	12×10^{-4}	0

3.0 Results and Discussion

Immune functions of innate, humoral or cell-mediated origin are modulated by sympathetic signals and circulating hormone levels during health and disease in a dose and receptor-type-dependent manner [1, 10, 12, 51]. *In vitro* studies from our laboratory have shown that adrenergic stimulation through α 1-, α 2- or β 2- ARs using specific agonists non-specifically inhibit lymphoproliferation through distinct signaling pathways: α 1-ARs mediated immunosuppressive effects by inhibiting IFN- γ production, α 2-AR activated the NF- κ B, p-Akt and NO pathways and β 2-AR activation involved IL-6, NO and NF- κ B signaling cascades mediating immunosuppression [17, 18]. On the other hand, treatment of lymphocytes with 17 β -estradiol enhanced proliferation in a dose and receptor subtype specific manner through p-ERK, p-CREB and p-Akt involving IFN- γ and compensatory mechanisms including antioxidant enzymes [4, 52]. Our studies have shown that co-treatment of lymphocytes with 17 β -estradiol and adrenergic agonists lead to 17 β -estradiol-mediated over-ride of adrenergic immunosuppression in a dose-dependent, AR-subtype independent manner [17, 18].

In the present study, we have modelled these signaling pathways *in silico* using the MATLAB Simbiology toolbox. Due to difficulties in conducting the experiments using NE, the *in vitro* studies were conducted using receptor-specific agonists and antagonists. While these experiments are highly beneficial in elucidating the dose-dependent effects on specific adrenoceptor sub-types, they cannot be considered as absolute indicators of NE-mediated effects. This is because when NE is added to the cells, depending on its relative affinity for the individual receptor subtypes, it may bind proportionally to all the ARs triggering a wide variety of downstream signals. The cumulative effects of these signals are likely to be different from the outcomes of receptor-subtype-specific signaling fates. In order to overcome this problem, the computational model was constructed on the basis of the data obtained from *in vitro* studies and all three ARs

studied were simultaneously activated to study the outcome. Based on previous findings, an attempt was made to incorporate cross-talks between these pathways by using common signaling molecule pools (Fig. 1).

As expected, the simulation of lymphocytes with adrenergic agonists, phenylephrine, clonidine, and terbutaline enhanced p-CREB and p-ERK expression (Fig. 3). 17 β -estradiol behaved similarly in the presence and absence of adrenergic agonists enhancing cAMP, p-ERK, and p-CREB expression suggesting that activation of cAMP may be crucial to 17 β -estradiol-mediated over-ride of adrenergic immunosuppression (Fig. 2 and 4).

A significant role is played by compensatory mechanisms such as antioxidant enzyme apart from signaling molecules, to influence the proliferative/apoptotic milieu of a cell by balancing free radical load including superoxides and peroxynitrites to name a few. These free radicals released as by-products following immune responses or during neurotransmitter release in secondary lymphoid organs may accumulate over the years and contribute to denervation of sympathetic noradrenergic fibers leading to impaired neuroendocrine-immune homeostasis setting the stage for age-associated diseases [7]. Studies from our lab and others have documented ER-subtype dependent increase in SOD and GPx activities in lymphocytes stimulated with estrogen [4, 53-58,]. Adrenergic stimulation also enhanced SOD and catalase activities *in vitro* which were suppressed upon coincubation with 17 β -estradiol indicating cross-talk between the two pathways leading to diminutive effects [18]. Along these lines, previous studies have implicated the involvement of PKA and ERK pathways, which when inhibited, reversed terbutaline-mediated increase in SOD and CAT activities [4, 17,18]. It is possible that these signaling molecules play a regulatory role in the expression and activity of these enzymes, thereby, exerting immunomodulatory effects [59,60]. In our model, adrenergic activation, 17 β -estradiol treatment,

and their co-treatment decrease superoxide formation but enhance peroxynitrites, although 17 β -estradiol treatment or co-treatment alone was accompanied by an induction of antioxidant enzyme activities (SOD and CAT) (Fig. 2-4).

Cytokines play a crucial role in influencing immune functions thereby affecting survival/apoptosis. Previously we have shown that while activation of α 1-ARs decrease IFN- γ and increase IL-2 production, α 2- and β 2-AR activation did not alter both IFN- γ and IL-2 production [17,18]. However, treatment with 17 β -estradiol alone or 17 β -estradiol with adrenergic agonists significantly enhance IFN- γ production alone after 24 hours of treatment. We have reported dose-dependent increase in IFN- γ production with 17 β -estradiol alone or co-treated with α 1- and β 2-AR agonists. In agreement with these findings, sensitivity analysis show that stimulation of lymphocytes with α 1-AR agonist, phenylephrine, showed increased sensitivity to IFN- γ and p-CREB expression while β 2-AR agonist terbutaline showed increased sensitivity to IFN- γ , p-ERK and p-CREB expression (Fig. 3). Interestingly 17 β -estradiol signaling showed the highest sensitivity to IFN- γ , p-ERK, p-CREB, and cAMP suggesting a probable cause in the dynamics of 17 β -estradiol-mediated signals that predispose it to over-ride adrenergic signals (Fig. 2 and 4).

In order to assess the likely effects of the signals and their cross-talks on proliferation, end-point signals were classified as either pro-apoptotic or survival signals. Plots obtained at the end of 72 hours indicate that while adrenergic stimulation was predominantly pro-apoptotic signals, 17 β -estradiol signals were pro-survival (Fig. 2 and 3). Dose-dependent role of 17 β -estradiol could be seen by increasing the 17 β -estradiol concentration by 10-fold leading to further increase in proliferation signals reversing the balance in favor of proliferation over apoptosis after 72 hours (Fig. 5). This is in accordance with the *in vitro* evidence generated in previous studies where all

the adrenergic agonists decreased proliferation while 17β -estradiol played a dose-dependent role in increasing proliferation of lymphocytes.

Modeling estrogen and adrenergic stimulation-mediated signals will help us to understand variations in the expression of downstream molecular markers with age- and disease-associated variations in kinetic parameters and concentrations and thereby providing an effective tool for understanding the alterations in the cross talk between the pathways in health, aging, and diseases.

Acknowledgement: Supported by the Department of Science and Technology (F.No. SR/SO/HS-46/2007 and IFA15/LSBM-154), Government of India, New Delhi.

References

1. Ader R, Felten D, Cohen N. Psychoneuroimmunology. 3rd Edition. Academic Press; San Diego, CA. 2001.
2. Priyanka HP, Sharma U, Gopinath S, Sharma V, Hima L, ThyagaRajan S. Menstrual cycle and reproductive aging alters immune reactivity, NGF expression, antioxidant enzyme activities, and intracellular signaling pathways in the peripheral blood mononuclear cells of healthy women. *Brain Behavior Immunity*. 2013; 32: 131–143.
3. ThyagaRajan S, Priyanka HP. Bidirectional communication between the neuroendocrine system and the immune system: relevance to health and diseases. *Annals of Neurosciences*. 2011; 19: 40-46.
4. Priyanka HP, Krishnan HC, Singh RV, Hima L, ThyagaRajan S. Estrogen modulates in vitro T cell responses in a concentration- and receptor dependent manner: effects on intracellular molecular targets and antioxidant enzymes. *Molecular Immunology*. 2013; 56: 328–339.

5. Lu JKH. Changes in ovarian function and gonadotropin and prolactin secretion in aging female rats. In: Meites J (Ed). *Neuroendocrinology of Aging*, (pp.103-122), Plenum, New York. 1983.
6. Wise PM. Alterations in the proestrous pattern of median eminence LHRH, serum LH, FSH, estradiol and progesterone concentrations in middle-aged rats. *Life Sciences*. 1982; 31: 165-173.
7. ThyagaRajan S, Madden KS, Teruya B, Stevens SY, Felten DL, Bellinger DL. (2011). Age-associated alterations in sympathetic noradrenergic innervation of primary and secondary lymphoid organs in female Fischer 344 rats. *Journal of Neuroimmunology*. 2011; 233: 54-64.
8. Lang TJ. Estrogen as an immunomodulator. *Clinical Immunology*. 2004; 113: 224-230.
9. Meites J. Aging: hypothalamic catecholamines, neuroendocrine-immuneinteractions, and dietary restriction. *Proceedings of the Society for Experimental Biology and Medicine*. 1990; 195: 304-311.
10. Felten DL, Felten SY, Bellinger DL, Carlson SL, Ackerman KD, Madden KS, Olschowki JA, Livnat S. Noradrenergic sympathetic neural interactions with the immune system: structure and function. *Immunological Reviews*. 1987; 100: 225-260.
11. Madden KS. Catecholamines, sympathetic innervation, and immunity. *Brain Behavior Immunity*, 2003; 17: S5-S10.
12. Madden KS, Felten DL. Experimental basis for neural-immune interactions. *Physiological Reviews*. 1995; 75: 77-106.
13. Nance DM, Sanders VM. Autonomic innervation and regulation of the immune system (1987-2007). *Brain Behavior Immunity*. 2007; 21: 736-774.

14. Cunningham M, Gilkeson G. Estrogen receptors in immunity and autoimmunity. *Clinical Reviews in Allergy and Immunology*. 2011; 40: 66-73.
15. Bao JY, Huang Y, Wang F, Peng YP, Qiu YH. Expression of alpha-AR subtypes in T lymphocytes and role of the alpha-ARs in mediating modulation of T cell function. *Neuroimmunomodulation*. 2007; 14: 344-353.
16. Sanders VM. The beta2-adrenergic receptor on T and B lymphocytes: do we understand it yet? *Brain Behavior Immunity*. 2012; 26: 195-200.
17. Priyanka HP, ThyagaRajan S. Selective modulation of lymphoproliferation and cytokine production via intracellular signaling targets by α 1- and α 2-adrenoceptors and estrogen in splenocytes. *International Immunopharmacology*. 2013; 17: 774–784.
18. Priyanka HP, Pratap UP, Singh RV, ThyagaRajan S. Estrogen modulates β 2-adrenoceptor-induced cell-mediated and inflammatory immune responses through ER- α involving distinct intracellular signaling pathways, antioxidant enzymes, and nitric oxide. *Cellular Immunology*. 2014; 292: 1-8.
19. Ricci A, Bronzetti E, Conterno A, Greco S, Mulatero P, Schena M, Schiavone D, Tayebati SK, Veglio F, Amenta F. Alpha1-adrenergic receptor subtypes in human peripheral blood lymphocytes. *Hypertension*. 1999; 33(2): 708-712.
20. Pugazhenth S, Nesterova A, Sable C, Heidenreich AK, Boxer ML, Heasley EL, Reusch JEB. Akt/Protein Kinase B Up-regulates Bcl-2 Expression through cAMP-response Element-binding Protein. *The Journal of Biological Chemistry* 2000; 275: 10761-10766.
21. Titinchi S, Clark B. Alpha 2-adrenoceptors in human lymphocytes: direct characterisation by [3H] yohimbine binding. *Biochemical and Biophysical Research Communications*. 1984; 31: 1-7.

22. Mori M, Regulation of nitric oxide synthesis and apoptosis by arginase and arginine recycling. *J Nutr.* 2007; 137 (6) S2: 1616S-1620S.
23. Hataoka I, Okayama M, Sugi M, Inoue H, Takishima T, Shirato K. Decrease in beta-adrenergic receptors of lymphocytes in spontaneously occurring acute asthma. *Chest.* 1993; 104: 508-514.
24. van den Meiracker AH, Man in't Veld AJ, Boomsma F, Fischberg DJ, Molinoff PB, Schalekamp MA. Hemodynamic and beta-adrenergic receptor adaptations during long-term beta-adrenoceptor blockade. Studies with acebutolol, atenolol, pindolol, and propranolol in hypertensive patients. *Circulation.* 1989; 80 (4): 903-14.
25. Bongioanni P, Lombardo F, Fioretti C, Meucci G. T-lymphocyte immunointerferon receptors in patients with multiple sclerosis. *Journal of Neurology.* 1996; 243: 605-610.
26. Graham RM, Perez DM, Hwa J, Piascik MT. Alpha 1-adrenergic receptor subtypes. Molecular structure, function, and signaling. *Circ Res.* 1996, 78: 737-749.
27. Michel MC, Kenny B, Schwinn DA. Classification of alpha 1-adrenoceptor subtypes. *Naunyn Schmiedebergs Arch Pharmacol* 1995, 352:1-10.
28. Cotecchia S, Stanasila L, Diviani D, Björklöf K, Rossier O, Fanelli F. Structural determinants involved in the activation and regulation of G protein-coupled receptors: lessons from the alpha1- adrenergic receptor subtypes. *Biol Cell* 2004, 96: 327-333.
29. Cotecchia S, Björklöf K, Rossier O, Stanasila L, Greasley P, Fanelli F. The alpha1b-adrenergic receptor subtype: molecular properties and physiological implications. *J Recept Signal Transduct Res* 2002, 22: 1-16.
30. Giovannitti Jr JA, Thoms SM, Crawford JJ. Alpha-2 adrenergic receptor agonists: a review of current clinical applications. *Anesthesia Progress* 2015, 62: 31-38.

31. Wijeyesundera DN, Bender JS, Beattie WS. Alpha-2 adrenergic agonists for the prevention of cardiac complications among patients undergoing surgery. *Cochrane Database Syst Rev* 2009, 7.
32. Arnsten AF, Steere JC, Hunt RD. The contribution of alpha 2-noradrenergic mechanisms of prefrontal cortical cognitive function. Potential significance for attention-deficit hyperactivity disorder. *Arch Gen Psychiatry* 1996, 53: 448-455.
33. Carlson S, Tanila H, Rama P, Mecke E, Pertovaara A. Effects of medetomidine, an alpha-2 adrenoceptor agonist, and atipamezole, an alpha-2 antagonist, on spatial memory performance in adult and aged rats. *Behav Neural Biol* 1992, 58:113-119.
34. Wagner JP, Seidler FJ, Schachar FH, Slotkin TA. Beta adrenergic control of c-fos protooncogene expression in developing rat brain regions. *J Pharmacol Exp Ther* 1994, 269: 1292-1299.
35. Ling L, Haraguchi K, Ohta K, Endo T, Onaya T. β 2-Adrenergic receptor mRNA is overexpressed in neoplastic human thyroid tissues. *Endocrinology* 1992, 130: 547-549.
36. Re G, Badino P, Novelli A, Girardi C, DiCarlo F. Evidence for functional β -adrenoceptor subtypes in CG-5 breast cancer cells. *Pharmacol Res* 1996, 33: 255-260.
37. MacEwan DJ, Milligan G. Up-regulation of a constitutively active form of the β 2-adrenoceptor by sustained treatment with inverse agonists but not antagonists. *FEBS Lett* 1996, 399: 108-112.
38. Vandewalle B, Revillion F, Lefebvre J. Functional β -adrenergic receptors in breast cancer cells. *J Cancer Res Clin Oncol* 1990, 116: 303-306.
39. Chaudhry A, Granneman JG. Developmental changes in adenylyl cyclase and GTP binding proteins in brown fat. *Amer J Physiol* 1991, 261: R403-R411.

40. Shakhar G, Ben-Eliyahu S. In vivo β -adrenergic stimulation suppresses natural killer activity and compromises resistance to tumor metastasis in rats. *J Immunol* 1998, 160: 3251-3258.
41. Pullar CE, Isseroff RR. The beta 2-adrenergic receptor activates pro-migratory and pro-proliferative pathways in dermal fibroblasts via divergent mechanisms. *J Cell Sci* 2006, 119: 592-602.
42. Yin F, Wang YY, Du JH, Li C, Lu ZZ, Han C, Zhang YY. Noncanonical cAMP pathway and p38 MAPK mediate beta2-adrenergic receptor-induced IL-6 production in neonatal mouse cardiac fibroblasts. *J Mol Cell Cardiol* 2006, 40: 384-393.
43. Slotkin TA, Zhang J, Dancel R, Garcia SJ, Willis C, Seidler FJ. Beta-adrenoceptor signaling and its control of cell replication in MDA-MB-231 human breast cancer cells. *Breast Cancer Res Treat* 2000, 60:153-166.
44. Priyanka HP, Singh RV, Pratap UP, ThyagaRajan S. Estrogen modulates β 2-adrenoceptor-induced cell-mediated and inflammatory immune responses through ER- α involving distinct intracellular signaling pathways, antioxidant enzymes, and nitric oxide. *Cell Immunol.* 2014, 292:1-8.
45. Li-Han Hsu, Nei-Min Chu, Yung-Feng Lin and Shu-Huei Kao. G-Protein Coupled Estrogen Receptor in Breast Cancer. *Int J Mol Sci* 2019, 20: 306.
46. Dennis MK, Burai R, Ramesh C, Petrie WK, Alcon SN, et al. In vivo effects of a GPR30 antagonist. *Nat. Chem. Biol.* 2009, 5: 421-427.
47. Pupo M, Maggiolini M, Musti AM. GPER mediates non-genomic effects of estrogen. *Methods Mol. Biol* 2016, 1366: 471-488.

48. Aiello F, Carullo G, Giordano F, Spina E, Nigro A, et al. Identification of breast cancer inhibitors specific for G protein-coupled estrogen receptor (GPER)-expressing cells. *Chem Med Chem*. 2017, 12: 1279-1285.
49. Mak HY, Hoare S, Henttu PM, Parker MG. Molecular determinants of the estrogen receptor–coactivator interface. *Mol Cell Biol* 1999, 19: 3895-3903.
50. Brzozowski AM, Pike AC, Dauter Z, et al. Molecular basis of agonism and antagonism in the oestrogen receptor. *Nature* 1997, 389: 753-758.
51. Bellinger DL, Lorton D. Autonomic regulation of cellular immune function. *Autonomic Neuroscience*. 2014; 182: 15-41.
52. Kale P, Mohanty A, Mishra M, Pratap UP, Priyanka HP, ThyagaRajan S. Estrogen modulates neural–immune interactions through intracellular signaling pathways and antioxidant enzyme activity in the spleen of middle-aged ovariectomized female rats. *Journal of Neuroimmunology*. 2014; 267: 7-15.
53. Abbas AM, Elsamanoudy AZ. Effects of 17 β -estradiol and antioxidant administration on oxidative stress and insulin resistance in ovariectomized rats. *Canadian Journal of Physiology and Pharmacology*. 2011; 89: 497-504.
54. Brann D, Raz L, Wang R, Vadlamudi R, Zhang Q. Oestrogen signalling and neuroprotection in cerebral ischaemia. *Journal of Neuroendocrinology*. 2012; 24: 34-47.
55. Simpkins JW, Green PS, Gridley KE. Role of estrogen replacement therapy in memory enhancement and the prevention of neuronal loss associated with Alzheimer's disease. *The American Journal of Medicine*. 1997; 103: S19-S25.

56. Stirone C, Duckles SP, Krause DN, Procaccio V. Estrogen increases mitochondrial efficiency and reduces oxidative stress in cerebral blood vessels. *Molecular Pharmacology*. 2005; 68: 959-965.
57. Pike ACW, Brzozowski AM, Hubbard RE. A structural biologist's view of the oestrogen receptor. *J Steroid Biochem Mol Biol* 2000, 74: 261-268.
58. Feng S. Estrogen receptor content of peripheral blood lymphocytes in patients with SLE. *Zhonghua Yi Xue Za Zhi*. 1991; 71(2): 1-3.
59. Sugino N, Karube-Harada A, Sakata A. Different mechanisms for the induction of copper-zinc superoxide dismutase and manganese superoxide dismutase by progesterone in human endometrial stromal cells. *Human Reproduction*. 2002; 17: 1709-1714.
60. Yano S, Yano N. Regulation of catalase enzyme activity by cell signaling molecules. *Molecular and Cellular Biochemistry*. 2002; 240 (1-2): 119-130.

Figure 1 *In silico* model of adrenergic [1A] and estrogen [1B] signaling cascades in lymphocytes: The cross-talk between the adrenergic and estrogen-mediated signals result in specific immunomodulatory effects depending upon the estrogen concentration. The layout of the signaling pathway is elucidated from receptors to transduction into the cytosol and nuclear translocation of signaling molecules leading to specific outcomes.

Figure 2 *Expression of molecular markers (2A), cytokines (2B), antioxidant enzymes (2C) and survival/apoptosis signals (2D) by estrogen: Simulation of lymphocytes treated with 10^{-6} M Estrogen for 24 hours.*

Figure 3 *Expression of molecular markers (3A), cytokines (3B), antioxidant enzymes (3C) and survival/apoptosis signals (3D) by terbutaline, phenylephrine and clonidine: Simulation of lymphocytes treated with terbutaline (10⁻⁶ M), phenylephrine (10⁻⁶ M) and clonidine (10⁻⁶ M) for 24 hours.*

Figure 4 *Expression of molecular markers (4A), cytokines (4B), antioxidant enzymes (4C) and survival/apoptosis signals (4D) by terbutaline, phenylephrine and clonidine in the presence of estrogen: Simulation of lymphocytes treated with terbutaline (10^{-6} M), phenylephrine (10^{-6} M) and clonidine (10^{-6} M) in the presence of estrogen (10^{-6} M) for 24 hours.*

Figure 5 *Effects of increasing doses of estrogen on survival/apoptosis signals by terbutaline, phenylephrine and clonidine: Simulation of lymphocytes treated with terbutaline (10^{-6} M), phenylephrine (10^{-6} M) and clonidine (10^{-6} M) in the presence of increasing doses of estrogen (10^{-6} M (5A), 10^{-5} M (5B), 10^{-4} M (5C), 10^{-3} M (5D)) for 72 hours.*

Supplementary Figures

Supplementary Figure 1: Simulation of Estrogen Signaling: Expression of molecular markers: p-ERK, p-CREB, cAMP and p-Akt upon stimulation with Estrogen 10^{-9} M (A), 10^{-6} M (B) and 10^{-3} M (C) after 24 hours and their sensitivities relative to Estrogen (D).

Supplementary Figure 2: Simulation of Estrogen Signaling: Expression of cytokines: IFN- γ and IL-2 upon stimulation with Estrogen 10^{-9} M (A), 10^{-6} M (B) and 10^{-3} M (C) after 24 hours and their sensitivities relative to Estrogen (D).

Supplementary Figure 3: Simulation of Estrogen Signaling: Expression of antioxidant enzymes: Catalase (CAT), Superoxide Dismutase (SOD), and superoxides and peroxynitrites upon stimulation with Estrogen 10^{-9} M (A), 10^{-6} M (B) and 10^{-3} M (C) after 24 hours and their sensitivities relative to Estrogen (D).

Supplementary Figure 4: Simulation of Estrogen Signaling: Expression of survival signal and apoptosis upon stimulation with Estrogen 10^{-9} M (A), 10^{-6} M (B) and 10^{-3} M (C) after 72 hours and their sensitivities relative to Estrogen (D).

Supplementary Figure 5: Simulation of Terbutaline Signaling: Expression of molecular markers: p-ERK, p-CREB, cAMP and p-Akt upon stimulation with Terbutaline 10^{-9} M (A), 10^{-6} M (B) and 10^{-3} M (C) after 24 hours and their sensitivities relative to Terbutaline (D).

Supplementary Figure 6: Simulation of Terbutaline Signaling: Expression of cytokines: IFN- γ and IL-2 upon stimulation with Terbutaline 10^{-9} M (A), 10^{-6} M (B) and 10^{-3} M (C) after 24 hours and their sensitivities relative to Terbutaline (D).

Supplementary Figure 7: Simulation of Terbutaline Signaling: Expression of antioxidant enzymes: Catalase (CAT), Superoxide Dismutase (SOD), and superoxides and peroxynitrites upon stimulation with Terbutaline 10^{-9} M (A), 10^{-6} M (B) and 10^{-3} M (C) after 24 hours and their sensitivities relative to Terbutaline (D).

Supplementary Figure 8: Simulation of Terbutaline Signaling: Expression of survival signal and apoptosis upon stimulation with Terbutaline 10^{-9} M (A), 10^{-6} M (B) and 10^{-3} M (C) after 72 hours and their sensitivities relative to Terbutaline (D).

Supplementary Figure 9: Simulation of Phenylephrine Signaling: Expression of molecular markers: p-ERK, p-CREB, cAMP and p-Akt upon stimulation with Phenylephrine 10^{-9} M (A), 10^{-6} M (B) and 10^{-3} M (C) after 24 hours and their sensitivities relative to Phenylephrine (D).

Supplementary Figure 10: Simulation of Phenylephrine Signaling: Expression of cytokines: IFN- γ and IL-2 upon stimulation with Phenylephrine 10^{-9} M (A), 10^{-6} M (B) and 10^{-3} M (C) after 24 hours and their sensitivities relative to Phenylephrine (D).

Supplementary Figure 11: Simulation of Phenylephrine Signaling: Expression of antioxidant enzymes: Catalase (CAT), Superoxide Dismutase (SOD), and superoxides and peroxyntrites upon stimulation with Phenylephrine 10^{-9} M (A), 10^{-6} M (B) and 10^{-3} M (C) after 24 hours and their sensitivities relative to Phenylephrine (D).

Supplementary Figure 12: Simulation of Phenylephrine Signaling: Expression of survival signal and apoptosis upon stimulation with Phenylephrine 10^{-9} M (A), 10^{-6} M (B) and 10^{-3} M (C) after 72 hours and their sensitivities relative to Phenylephrine (D).

Supplementary Figure 13: Simulation of Clonidine Signaling: Expression of molecular markers: p-ERK, p-CREB, cAMP and p-Akt upon stimulation with Clonidine 10^{-9} M (A), 10^{-6} M (B) and 10^{-3} M (C) after 24 hours and their sensitivities relative to Clonidine (D).

Supplementary Figure 14: Simulation of Clonidine Signaling: Expression of cytokines: IFN- γ and IL-2 upon stimulation with Clonidine 10^{-9} M (A), 10^{-6} M (B) and 10^{-3} M (C) after 24 hours and their sensitivities relative to Clonidine (D).

Supplementary Figure 15: Simulation of Clonidine Signaling: Expression of antioxidant enzymes: Catalase (CAT), Superoxide Dismutase (SOD), and superoxides and peroxynitrites upon stimulation with Clonidine 10^{-9} M (A), 10^{-6} M (B) and 10^{-3} M (C) after 24 hours and their sensitivities relative to Clonidine (D).

Supplementary Figure 16: Simulation of Clonidine Signaling: Expression of survival signal and apoptosis upon stimulation with Clonidine 10^{-9} M (A), 10^{-6} M (B) and 10^{-3} M (C) after 72 hours and their sensitivities relative to Clonidine (D).

Supplementary Figure 17: Simulation of Terbutaline+Estrogen Signaling: Expression of molecular markers: p-ERK, p-CREB, cAMP and p-Akt upon stimulation with Terbutaline 10^{-9} M (A), 10^{-6} M (B) and 10^{-3} M (C) +Estrogen 10^{-6} M after 24 hours and their sensitivities relative to Terbutaline+Estrogen (D).

Supplementary Figure 18: Simulation of Terbutaline+Estrogen Signaling: Expression of cytokines: IFN- γ and IL-2 upon stimulation with Terbutaline 10^{-9} M (A), 10^{-6} M (B) and 10^{-3} M (C) +Estrogen 10^{-6} M after 24 hours and their sensitivities relative to Terbutaline+Estrogen (D).

Supplementary Figure 19: Simulation of Terbutaline+Estrogen Signaling: Expression of antioxidant enzymes: Catalase (CAT), Superoxide Dismutase (SOD), and superoxides and peroxynitrites upon stimulation with Terbutaline 10^{-9} M (A), 10^{-6} M (B) and 10^{-3} M (C) +Estrogen 10^{-6} M after 24 hours and their sensitivities relative to Terbutaline+Estrogen (D).

Supplementary Figure 20: Simulation of Terbutaline+Estrogen Signaling: Expression of survival signal and apoptosis upon stimulation with Terbutaline 10^{-9} M (A), 10^{-6} M (B) and 10^{-3} M (C) +Estrogen 10^{-6} M after 72 hours and their sensitivities relative to Terbutaline+Estrogen (D).

Supplementary Figure 21: Simulation of Phenylephrine+Estrogen Signaling: Expression of molecular markers: p-ERK, p-CREB, cAMP and p-Akt upon stimulation with Phenylephrine 10^{-9} M (A), 10^{-6} M (B) and 10^{-3} M (C) +Estrogen 10^{-6} M after 24 hours and their sensitivities relative to Phenylephrine+Estrogen (D).

Supplementary Figure 22: Simulation of Phenylephrine+Estrogen Signaling: Expression of cytokines: IFN- γ and IL-2 upon stimulation with Phenylephrine 10⁻⁹M (A), 10⁻⁶M (B) and 10⁻³M (C) +Estrogen 10⁻⁶M after 24 hours and their sensitivities relative to Phenylephrine+Estrogen (D).

Supplementary Figure 23: Simulation of Phenylephrine+Estrogen Signaling: Expression of antioxidant enzymes: Catalase (CAT), Superoxide Dismutase (SOD), and superoxides and peroxynitrites upon stimulation with Phenylephrine 10^{-9} M (A), 10^{-6} M (B) and 10^{-3} M (C) +Estrogen 10^{-6} M after 24 hours and their sensitivities relative to Phenylephrine+Estrogen (D).

Supplementary Figure 24: Simulation of Phenylephrine+Estrogen Signaling: Expression of survival signal and apoptosis upon stimulation with Phenylephrine 10^{-9} M (A), 10^{-6} M (B) and 10^{-3} M (C) +Estrogen 10^{-6} M after 72 hours and their sensitivities relative to Phenylephrine+Estrogen

Supplementary Figure 25: Simulation of Clonidine+Estrogen Signaling: Expression of molecular markers: p-ERK, p-CREB, cAMP and p-Akt upon stimulation with Clonidine 10^{-9} M (A), 10^{-6} M (B) and 10^{-3} M (C) +Estrogen 10^{-6} M after 24 hours and their sensitivities relative to Clonidine+Estrogen (D).

Supplementary Figure 26: Simulation of Clonidine+Estrogen Signaling: Expression of cytokines: IFN- γ and IL-2 upon stimulation with Clonidine 10^{-9} M (A), 10^{-6} M (B) and 10^{-3} M (C) +Estrogen 10^{-6} M after 24 hours and their sensitivities relative to Clonidine+Estrogen (D).

Supplementary Figure 27: Simulation of Clonidine+Estrogen Signaling: Expression of antioxidant enzymes: Catalase (CAT), Superoxide Dismutase (SOD), and superoxides and peroxynitrites upon stimulation with Clonidine 10^{-9} M (A), 10^{-6} M (B) and 10^{-3} M (C) +Estrogen 10^{-6} M after 24 hours and their sensitivities relative to Clonidine+Estrogen (D).

Supplementary Figure 28: Simulation of Clonidine+Estrogen Signaling: Expression of survival signal and apoptosis upon stimulation with Clonidine 10^{-9} M (A), 10^{-6} M (B) and 10^{-3} M (C) +Estrogen after 72 hours and their sensitivities relative to Clonidine+Estrogen (D).

Supplementary Index-2

M Code for Sensitivity Analysis:

```
function data = runsensitivity(modelobj, cs, variants)
% RUNSENSITIVITY calculate the sensitivities for SimBiology model,
% modelobj using the variant object(s), variants. Variant object
% settings supercede model property-values.
%
% To calculate the sensitivities of X with respect to Y, X is an output
% factor and Y is an input factor.

% Restore the configset after the task has run.
cleanup = onCleanup(@() restore(cs));

% Configure the configuration set for sensitivity analysis.
set(cs.SolverOptions, 'SensitivityAnalysis', true);

% Configure Normalization.
set(cs.SensitivityAnalysisOptions, 'Normalization', 'none');

% Configure the inputs.
input1 = modelobj.Compartments(1).Species(22);
input2 = modelobj.Compartments(1).Species(5);
set(cs.SensitivityAnalysisOptions, 'Inputs', [input1, input2]);

% Configure the output factors.
output1 = modelobj.Compartments(1).Species(44);
output2 = modelobj.Compartments(1).Species(45);
output3 = modelobj.Compartments(1).Species(16);
output4 = modelobj.Compartments(1).Species(47);
output5 = modelobj.Compartments(1).Species(34);
output6 = modelobj.Compartments(1).Species(60);
output7 = modelobj.Compartments(1).Species(9);
output8 = modelobj.Compartments(1).Species(8);
output9 = modelobj.Compartments(1).Species(33);
output10 = modelobj.Compartments(1).Species(24);
output11 = modelobj.Compartments(1).Species(55);
output12 = modelobj.Compartments(1).Species(11);
output13 = modelobj.Compartments(1).Species(42);
output14 = modelobj.Compartments(1).Species(52);
output15 = modelobj.Compartments(1).Species(57);
output16 = modelobj.Compartments(1).Species(21);
output17 = modelobj.Compartments(1).Species(51);
output18 = modelobj.Compartments(1).Species(30);
output19 = modelobj.Compartments(1).Species(54);
output20 = modelobj.Compartments(1).Species(36);
```



```
set(cs.SensitivityAnalysisOptions, 'Outputs', [output1, output2, output3, output4, output5,
output6, output7, output8, output9, output10, output11, output12, output13, output14, output15,
output16, output17, output18, output19, output20]);
```

```
% Run simulation.
```

```
data = sbiosimulate(modelobj, cs, variants, []);
```

```
% Plot the results.
```

```
plottype_Sensitivity_Matrix_Subplot(data, '<all>', '<all>');
```

```
plottype_Time(data, '<all>', 'one axes', "");
```

```
% -----
function restore(cs)
```

```
% Turn off sensitivity analysis.
```

```
try
```

```
    set(cs.SolverOptions, 'SensitivityAnalysis', false);
```

```
    set(cs.SensitivityAnalysisOptions, 'Inputs', []);
```

```
    set(cs.SensitivityAnalysisOptions, 'Outputs', []);
```

```
catch ex
```

```
end
```

```
% -----
function plottype_Sensitivity_Matrix_Subplot(tobj, input, output)
%SENSITIVITY_MATRIX_SUBPLOT Plots sensitivity Matrix using time integral.
%
% Plot the sensitivity matrix using the time integral for the sensitivities
% for the specified input and output factors.
%
% See also SBIOGETSENSMATRIX.
```

```
% Create a subplot if there is more than one run.
```

```
if (length(tobj) > 1)
```

```
    sbiosubplot(tobj, @sensubplotdata, output, input, false);
```

```
else
```

```
    sensubplotdata(tobj, output, input);
```

```
end
```

```
% -----
function sensubplotdata(tobj, x, y)
```

```
% Parse the input arguments.
```

```
if strcmpi(y, '<all>')
```

```
    y = {};
```

```

end

if strcmpi(x, '<all>')
    x = {};
end

[t, R, states, inputs] = getsensmatrix(tobj, x, y);

[~, in, out] = size(R);
result = zeros(in, out);

for i = 1:in
    for j = 1:out
        index = ~isnan(R(:,i,j)) & ~isinf(R(:,i,j));
        result(i,j) = trapz(t(index), abs(R(index,i,j)));
    end
end

% Plot the data.
if in == 1 || out == 1
    if out == 1 && in > 1
        hbar = barh(result);
        haxes = get(hbar(1), 'Parent');
        set(haxes, 'ytick', 1:length(states));
        set(haxes, 'yticklabel', states, 'TickLabelInterpreter','none');
        xlabel(sprintf('Sensitivity relative to: %s', inputs{1}));
        ylabel('States');
    elseif in == 1
        hbar = bar(result);
        haxes = get(hbar(1), 'Parent');
        set(haxes, 'xtick', 1:length(inputs));
        set(haxes, 'xticklabel', inputs);
        ylabel(sprintf('Sensitivity of: %s', states{1}));
        xlabel('Parameters');
    end
    f = get(haxes, 'Parent');
    title('Sensitivity - Time Integral');
else
    hbar = bar3(result);
    view(2);

    title('Sensitivity Matrix - Time Integral');
    zlabel('Sensitivity');
    xlabel('Parameters');
    ylabel('States');
end

```

```

haxes = get(hbar(1), 'Parent');
set(haxes, 'PlotBoxAspectRatioMode', 'auto')
f = get(haxes, 'Parent');
while ~strcmp(get(f, 'type'), 'figure')
    f = get(f, 'Parent');
end
set(f, 'Renderer', 'zbuffer')

% Set the tick labels to the input and output names.
set(haxes, 'xtick', 1:length(inputs));
set(haxes, 'xticklabel', inputs);

set(haxes, 'ytick', 1:length(states));
set(haxes, 'yticklabel', states, 'TickLabelInterpreter', 'none');

% Color the bars by height.
for j = 1:length(hbar)
    zd = get(hbar(j), 'zdata');
    for i=1:6:size(zd,1)
        zd(i + [0 3 4], 2:3) = zd(i+1,2);
        zd(i + [1 2] ,[1 4]) = zd(i+1,2);
    end
    set(hbar(j), 'cdata', zd);
end

colorbar;
end

% turn off default axes interactions and axes toolbar
set(f, 'DefaultAxesToolbarVisible', 'off');
allAxes = findobj(f, '-class', 'matlab.graphics.axis.Axes');
set(allAxes, 'Toolbar', []);
arrayfun(@(ax)matlab.graphics.interaction.disableDefaultAxesInteractions(ax), allAxes);

% -----
function plottype_Time(tobj, y, plotStyle, axesStyle)
%TIME Plots states versus time.
%
% TIME(TOBJ, Y, PLOTSTYLE, PROPS) plots the results of the simulation
% for the species with the specified Y versus time.
%
% If PLOTSTYLE is 'one axes' then data from each run is plotted into one
% axes. If PLOTSTYLE is 'trellis' then data from each run is plotted
% into its own subplot.

```

```
%
% If Y is '<all>' then all data will be plotted.
%
% AXESSTYLE is a structure that contains axes property value pairs.
%
% See also GETDATA, SELECTBYNAME.

if ~isempty(tobj(1).RunInfo.ConfigSet) &&
tobj(1).RunInfo.ConfigSet.CompileOptions.UnitConversion &&
all(strcmp({tobj.TimeUnits},tobj(1).TimeUnits)) && ~isempty(tobj(1).TimeUnits)
    labelX = ['Time (' tobj(1).TimeUnits ')'];
else
    labelX = 'Time';
end

% Get the labels for the plot.
labelArgs = timeGetLabels(axesStyle, 'States versus Time', labelX, 'States');

if (length(tobj) > 1)
    switch (plotStyle)
    case 'one axes'
        haxes = sbiplot(tobj, @timeplotdata, [], y, labelArgs{:});
    case 'trellis'
        htrellis = sbiotrellis(tobj,@timesubplotdata, [], y, labelArgs{:});
        haxes = htrellis.plots;
    end

    % Configure the axes properties.
    if isfield(axesStyle, 'Properties')
        set(haxes, axesStyle.Properties);
    end
else
    % Plot Data.
    handles = timesubplotdata(tobj, [], y);
    haxes = get(handles(1), 'Parent');

    % Configure the axes properties.
    if length(handles)>=1
        haxes = get(handles(1), 'Parent');
        if isfield(axesStyle, 'Properties')
            set(haxes, axesStyle.Properties);
        end
    else
        haxes = [];
    end
end
```

```

% Label the plot.
title(labelArgs{2});
xlabel(labelArgs{4});
ylabel(labelArgs{6});

% If Y is '<all>' get all the data names.
if strcmpi(y, '<all>')
    [~, ~, names] = getdata(tobj);
else
    names = y;
end

% Create legend.
leg = legend(names, 'Location', 'NorthEastOutside');
set(leg, 'Interpreter', 'none');

% turn off default axes interactions and axes toolbar
if ~isempty(haxes)
    f = get(haxes, 'Parent');
    set(f, 'DefaultAxesToolbarVisible', 'off');
    allAxes = findobj(f, '-class', 'matlab.graphics.axis.Axes');
    set(allAxes, 'Toolbar', []);
    arrayfun(@(ax)matlab.graphics.interaction.disableDefaultAxesInteractions(ax), allAxes);
end
end

%-----
function [handles, names] = timeplotdata(tobj, ~, y)

colors = get(gca, 'ColorOrder');
numColors = length(colors);

% Preallocate handles
if strcmpi(y, '<all>')
    [~, ~, names] = getdata(tobj(1));
else
    [~, ~, names] = selectbyname(tobj(1), y);
end
handles = zeros(length(names), length(tobj));

for i=1:length(tobj)
    % Get the data from the next run.
    nexttobj = tobj(i);

    % Get the data associated with y.
    if strcmpi(y, '<all>')

```

```

        [time, data, names] = getdata(nexttobj);
    else
        [time, data, names] = selectbyname(nexttobj, y);
    end

    % Error checking.
    if size(data,2) == 0
        error('Data specified do not exist. ');
    end
    set(gca, 'ColorOrderIndex', 1);
    % Plot data. If there is only one state use different colors for runs.
    if(size(data,2) == 1)
        hLine = plot(time, data, 'color', colors(mod(i-1, numColors)+1, :));
    else
        hLine = plot(time, data);
    end
    handles(:, i) = hLine;
end

% -----
function handles = timesubplotdata(tobj, ~, y)

% Get Data to be plotted.
if strcmpi(y, '<all>')
    [time, data] = getdata(tobj);
else
    [time, data] = selectbyname(tobj, y);
end

% Error checking.
if size(data,2) == 0
    error('Species specified do not exist. ');
end

% Plot Data.
handles = plot(time, data);

% -----
function out = timeGetLabels(axesStyle, labelTitle, labelX, labelY)

out = {'title', labelTitle, 'xlabel', labelX, 'ylabel', labelY};

if isfield(axesStyle, 'Labels')
    allLabels = axesStyle.Labels;

    if isfield(allLabels, 'Title')

```

```
        out{2} = allLabels.Title;
    end

    if isfield(allLabels, 'XLabel')
        out{4} = allLabels.XLabel;
    end

    if isfield(allLabels, 'YLabel')
        out{6} = allLabels.YLabel;
    end
end
```